Nextech Invest Ltd's Q1 2022 13F: 3 new positions
Form 13F-HR for the quarter ended Mar 31, 2022 · filed May 16, 2022 · 14 reported positions · accession 0001104659-22-060901
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Increased | REVOLUTION MEDICINES INC (RVMD) | 19.7% | 28.7% | +9.0 pts | +971K sh | +33% |
| New | MIRATI THERAPEUTICS INC (MRTX) | — | 4.1% | +4.1 pts | +173K sh | new |
| New | RELAY THERAPEUTICS INC (RLAY) | — | 4.1% | +4.1 pts | +475K sh | new |
| New | BLUEPRINT MEDICINES CORP (BPMC) | — | 3.4% | +3.4 pts | +188K sh | new |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 90.5% of the equity book
Changes in the top 10 this quarter: MRTX entered · RLAY entered · BPMC entered · KRON left · SPRY left · CCCC left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC (RVMD) | 19.7% | 28.7% | |
| 2 | EQRX INC (EQRX) | 23.5% | 15.5% | |
| 3 | KINNATE BIOPHARMA INC (KNTE) | 14.0% | 9.7% | |
| 4 | PMV PHARMACEUTICALS INC (PMVP) | 8.4% | 8.2% | |
| 5 | TYRA BIOSCIENCES INC (TYRA) | 9.3% | 7.7% | |
| 6 | ARVINAS INC (ARVN) | 6.2% | 5.5% | |
| 7 | MIRATI THERAPEUTICS INC (MRTX) | 0.0% | 4.1% | Entered the top 10 |
| 8 | RELAY THERAPEUTICS INC (RLAY) | 0.0% | 4.1% | Entered the top 10 |
| 9 | CULLINAN ONCOLOGY INC (CGEM) | 5.0% | 3.6% | |
| 10 | BLUEPRINT MEDICINES CORP (BPMC) | 0.0% | 3.4% | Entered the top 10 |
| — | KRONOS BIO INC (KRON) | 5.2% | 3.0% | Left the top 10 |
| — | SILVERBACK THERAPEUTICS INC (SPRY) | 3.4% | 1.9% | Left the top 10 |
| — | C4 THERAPEUTICS INC (CCCC) | 3.2% | 2.6% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).